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Abstract
Background: Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via
loss of PTEN and/or INPP4B is common. Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. We evaluated
the safety and efficacy of buparlisib in patients with metastatic triple-negative breast cancer.
Methods: This was a single-arm phase 2 study enrolling patients with triple-negative metastatic breast cancer.
Patients were treated with buparlisib at a starting dose of 100 mg daily. The primary endpoint was clinical benefit,
defined as confirmed complete response (CR), partial response (PR), or stable disease (SD) for ≥ 4 months, per RECI
ST 1.1. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and toxicity. A subset of
patients underwent pre- and on-treatment tumor tissue biopsies for correlative studies.
Results: Fifty patients were enrolled. Median number of cycles was 2 (range 1–10). The clinical benefit rate was
12% (6 patients, all SD ≥ 4 months). Median PFS was 1.8 months (95% confidence interval [CI] 1.6–2.3). Median OS
was 11.2 months (95% CI 6.2–25). The most frequent adverse events were fatigue (58% all grades, 8% grade 3),
nausea (34% all grades, none grade 3), hyperglycemia (34% all grades, 4% grade 3), and anorexia (30% all grades,
2% grade 3). Eighteen percent of patients experienced depression (12% grade 1, 6% grade 2) and anxiety (10%
grade 1, 8% grade 2). Alterations in PIK3CA/AKT1/PTEN were present in 6/27 patients with available targeted DNA
sequencing (MSK-IMPACT), 3 of whom achieved SD as best overall response though none with clinical benefit ≥ 4
months. Of five patients with paired baseline and on-treatment biopsies, reverse phase protein arrays (RPPA)
analysis demonstrated reduction of S6 phosphorylation in 2 of 3 patients who achieved SD, and in none of the
patients with progressive disease.
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Conclusions: Buparlisib was associated with prolonged SD in a very small subset of patients with triple-negative
breast cancer; however, no confirmed objective responses were observed. Downmodulation of key nodes in the
PI3K pathway was observed in patients who achieved SD. PI3K pathway inhibition alone may be insufficient as a
therapeutic strategy for triple-negative breast cancer.
Trial registration: NCT01790932. Registered on 13 February 2013; NCT01629615. Registered on 27 June 2012.
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Introduction
Triple-negative breast cancer (estrogen receptor [ER]-
negative, progesterone receptor [PgR]-negative, and hu-
man epidermal growth factor receptor 2 [HER2]-nega-
tive) accounts for approximately 12–17% of all breast
cancers and is associated with poor outcomes, with an
increase in the risk of recurrence compared to other
breast cancer subtypes and more frequent spread to vis-
ceral organs and the central nervous system (CNS) [1–
4]. Median survival after a diagnosis of metastatic triple-
negative breast cancer is only approximately 1 year with
current chemotherapy regimens [3, 5]. At the time this
study was designed, cytotoxic chemotherapy was the
mainstay of treatment, and no targeted or immunothera-
peutic agents had yet gained an indication in this setting.
The phosphatidylinositol-3-kinase (PI3K) pathway is in-
volved in diverse cellular functions, including cell growth
and metabolism, migration, proliferation, and survival [6].
The molecular alterations leading to activation of the PI3K
pathway in cancer are varied and include mutations in the
genes encoding the PI3K alpha (PIK3CA) and beta (PIK3CB)
catalytic subunits, AKT1 mutations, and loss of expression
of the phosphatidylinositol-3,4,5 trisphosphate (PIP3) phos-
phatases PTEN and INPP4B. Mutations in PIK3CA and
AKT1 are relatively uncommon in triple-negative breast
cancer [7]; however, loss of PTEN and/or INPP4B has been
reported in 30–60% of basal-like tumors [7–9].
Buparlisib (BKM120, Novartis) is an orally bioavail-
able, potent, pan-class I PI3K inhibitor. In the phase 1
dose-escalation study enrolling patients with advanced
solid tumors, 100mg daily was identified as the max-
imum tolerated dose, and one confirmed partial re-
sponse was observed in a patient with triple-negative
breast cancer [10, 11]. Dose-limiting toxicities were
mood alteration, rash, and hyperglycemia.
The primary objective of this phase 2 study was to
evaluate the clinical activity of buparlisib monotherapy
in patients with metastatic triple-negative breast cancer.
Secondary objectives included progression-free survival
(PFS), overall survival (OS), and further characterization
of the toxicity profile. A subset of patients underwent
pre- and on-treatment biopsies for correlative studies. If
sufficient clinical activity was observed in the first stage
of the study, planned biomarker analyses to define
potential expansion cohorts were to be performed in




The study enrolled patients with metastatic breast cancer
who met the following key criteria: pathologically con-
firmed invasive breast cancer, ER- and PgR-negative (de-
fined as < 1% staining by immunohistochemistry [IHC])
[12], and HER2-negative by IHC or FISH/CISH per local
assessment [13]. If a patient had more than one histo-
logical result, the most recent one was considered for in-
clusion. Eligibility criteria included age 18 years or older;
Eastern Cooperative Oncology Group performance status
0–2; at least one measurable lesion according to RECIST
1.1; adequate bone marrow, hepatic, and renal function;
and fasting plasma glucose ≤ 140mg/dL. Availability of an
archival tumor specimen was also required from primary
or metastatic disease. Key exclusion criteria were previous
treatment with any PI3K inhibitor; symptomatic CNS me-
tastases; concurrent use of moderate to strong modifiers
of CYP3A4; or pre-existing significant mood disorder, in-
cluding active major depressive episode, bipolar disorder,
schizophrenia; Common Terminology Criteria for Ad-
verse Events (CTCAE) grade ≥ 3 anxiety, or a history of
suicide attempt or homicidal ideation. When the trial first
opened, there was no limit on the number of prior lines of
chemotherapy for metastatic breast cancer. After 30 pa-
tients were enrolled, the trial was amended to restrict the
number of prior lines to 0–2 to include a less heavily pre-
treated population.
Study design
This was a single-arm, phase 2 study. Two parallel pro-
tocols enrolled patients in the USA (Dana-Farber Cancer
Institute, Boston, MA) or Spain (coordinating center,
Vall d’Hebron, Barcelona) with a pre-specified combined
analysis plan. All patients received buparlisib at a start-
ing dose of 100 mg once daily. The planned duration of
one cycle of therapy was 4 weeks. Buparlisib dose modi-
fications were per protocol according to a pre-defined
algorithm. Up to two dose reductions were allowed (to
80mg daily and 60 mg daily). Safety assessments,
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including fasting plasma glucose, were conducted every
2 weeks for the first 2 cycles, and then every 4 weeks.
Mood alterations were further assessed using the Patient
Health Questionnaire (PHQ)-9 and Generalized Anxiety
Disorder Scale (GAD)-7 on the same schedule [14, 15].
Adverse events were assessed according to the National
Cancer Institute CTCAE version 4.0. Tumor assessments
occurred every 2 cycles. Confirmation of response at
least 4 weeks later was required to deem a confirmed
complete response (CR) or partial response (PR). Paired
tumor biopsies at baseline and end of cycle 1 were re-
quested in patients with accessible disease. A minimum
of 10 patients with paired biopsies enrolled within the
first stage (prior to the interim analysis) was targeted.
Patients were treated until disease progression, un-
acceptable toxicity, or withdrawal of consent.
This trial was registered with the US National Institutes
of Health (ClinicalTrials.gov identifier: NCT01790932,
NCT01629615). All patients provided written informed
consent before the initiation of any study-related proce-
dures or treatments.
Study endpoints
The primary study endpoint was clinical benefit, defined
as confirmed CR, confirmed PR or stable disease (SD) ≥
4 months, as assessed by RECIST 1.1 [16]. Secondary
endpoints included PFS, OS, and toxicity profile. PFS
was defined as the time from date of enrollment until
date of disease progression or death of any cause, which-
ever occurred first. If patients were alive without disease
progression at the end of the study, their PFS time was
censored at the date of last radiographic tumor assess-
ment. OS was defined as time from date of enrollment
until date of death from any cause. If patients were alive
at the end of the study, their OS time was censored at
the date of last known alive.
Targeted DNA sequencing data
DNA was extracted from formalin-fixed paraffin-
embedded (FFPE) tumor tissue samples, either archival
tumor or research tumor tissue biopsies, for targeted
panel sequencing. Targeted panel next-generation se-
quencing was performed using MSK-IMPACT testing,
following previously described methods [17], using panel
version IMPACT410.
Proteomic data
Proteomic data were generated by reverse phase protein
arrays (RPPA) in 5 patients with available tissue from
paired baseline and on-treatment samples. RPPA was
performed in the MD Anderson Cancer Center Func-
tional Proteomics Core Facility as previously described
[18, 19]. Following sonication, samples were quantitated
with BCA Assay Kit and protein levels were expressed as
the mean expression values in log2. Lysates were probed
with antibodies validated for RPPA that are enriched for
components of the PI3K pathway. The RPPA data were
median-centered and scaled to one standard deviation
before performing analyses. RPPA level 4 was down-
loaded from the Cancer Proteome Atlas (TCPA) data
portal (www.TCPAportal.org) and samples with PAM50
intrinsic subtype classification were selected. The cluster
analyses were displayed using Java Treeview version 3.0.
Centroid linkage hierarchical clustering was performed
using Gene Cluster v3.0. Biomarker data were analyzed
using R (version 3.5.1).
The PI3K RPPA proteomic signature (PI3K score) was
calculated as a composite biomarker PI3K score = [pAkt +
pmTOR + pGSK3 + pS6K + pS6 + p4EBP1] – [INPP4b +
PTEN]10. v3.5.1 (http://cran.r-project.org).
Statistical analysis
The study was designed in two parts. In part 1, up to 50
patients were to be enrolled in order to describe the effi-
cacy of buparlisib in a molecularly unselected popula-
tion. An interim analysis was planned after the first 29
patients were enrolled (first stage). Assuming a prior dis-
tribution of beta (0.5, 9.5) for the response rate (p), the
early stopping criterion of prob (p < 0.05 | data) > 0.95
would lead to a stopping boundary of 0 patient with
clinical benefit out of the first 29 patients. The chosen
prior distribution yields a prior mean response rate of
0.05 based on a prior (hypothetical) sample size of 10
patients. If any patient experienced clinical benefit, part
1 of the study was to proceed to full accrual up to 50 pa-
tients (second stage). After 50 patients were enrolled,
tumor analysis was to be conducted, with correlation to
clinical benefit. If clinical benefit was observed in one or
more molecular subgroups (e.g., loss of PTEN or
INPP4B), then part 2 of the study would open to expand
specific subgroups. Patient disposition, efficacy, and
safety analyses were performed using SAS.
Results
Patients and treatment
Fifty women were enrolled between June 2012 and Sep-
tember 2014 (Table 1). Median age was 53 years (range
29–79). Forty-four (44/50, 88%) patients had received
neoadjuvant or adjuvant chemotherapy. Patients received
a median of 1.5 lines of prior chemotherapy for meta-
static disease (range 0–7).
Follow-up information is available through September
30, 2015, for a median follow-up time of 13.8 months.
The reasons for discontinuation of protocol therapy
were progressive disease (n = 41; 82%), unacceptable tox-
icity (n = 7; 14%), physician discretion (n = 1; 2%), and
withdrawal of consent (n = 1; 2%). Toxicities leading to
discontinuation were grade 2 or 3 rash (n = 3), persistent
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grade 2 or higher transaminitis (n = 1), grade 3 hypergly-
cemia (n = 1), grade 3 fatigue and grade 2 behavior alter-
ation (n = 1), and intercurrent illness (n = 1). At the time
of data-lock, all patients had discontinued protocol ther-
apy, 29 patients had died, 17 patients were still alive, and
4 patients were lost to follow-up.
Efficacy
Of 50 patients enrolled, 37 patients were evaluable for best
response, 12 patients were taken off treatment before the
first restaging evaluation due to clinical progression, and one
patient was taken off treatment early due to toxicity (Table 2).
The first stage of accrual had a protocol-specified target ac-
crual of 29 patients; however, one more patient was enrolled
in this stage (with prior approval of a deviation) due to the
protocol requirement to also enroll at least 10 patients with
paired metastatic biopsies. Out of the first 30 patients, 3 ex-
perienced SD ≥ 4months, meeting the study pre-defined pri-
mary endpoint of clinical benefit and failing to cross the
early stopping boundary. Accrual thus continued toward a
total of 50 patients, among which six (6/50, 12%) experi-
enced clinical benefit of SD≥ 4months. One patient had an
unconfirmed PR; however, there were no confirmed CR or
PR. Median PFS was 1.8months (95% CI 1.6–2.3) (Fig. 1a).
Median OS was 11.2months (95% CI 6.2–25) (Fig. 1b).
Safety
A total of 143 cycles of buparlisib were administered
(Supplemental Table 1). The median number of cycles
per patient was 2 (range 1–10). Dosing was held in 48%
of patients; however, only 7 (14%) patients required a
dose reduction. The most common reason for dose delay
or hold was hepatic toxicity (6 patients).
Adverse events are summarized in Table 3. The most fre-
quently reported adverse events (all relatedness) were fa-
tigue (58% all grades, 8% grade 3), nausea (34% all grades,
none grade 3), hyperglycemia (34% all grades, 4% grade 3),
and anorexia (30% all grades, 2% grade 3). Any grade de-
pression and anxiety were each reported in 9 patients, none
of which were grade 3. QTc prolongation was noted in 13
patients (10 [20%] grade 1; 3 [6%] grade 2; no grade 3 or 4).
As expected, hyperglycemia was noted, with one (2%) pa-
tient experiencing grade 2 and two (4%) patients experien-
cing grade 3 hyperglycemia. Three (6%) patients required a
Table 1 Baseline characteristics
Characteristic No. of patients (%)
Age, years










Hispanic or Latino 12 (24)
Non-Hispanic 37 (74)
Unknown 1 (2)
ECOG PS at baseline
0 32 (64)
1 18 (36)
Disease-free interval (from primary diagnosis to metastatic
diagnosis)
De novo metastatic disease 5 (10)
≤ 2 years 25 (50)
> 2 years 20 (40)
Sites of disease at inclusion
CNS 2 (4)
Lung or pleural effusion 13 (26)
Liver 5 (10)
Bone 8 (16)
Breast or chest wall 15 (30)
Lymph nodes 20 (40)
Soft tissue 2 (4)
Other 4 (8)
Previous treatment
Adjuvant or neoadjuvant chemotherapy 44 (88)
Adjuvant or neoadjuvant anthracycline 36 (72)
Adjuvant or neoadjuvant taxane 42 (84)
Lines of chemotherapy for metastatic or recurrent disease
Median (range) 1.5 (0–7)
None 7 (14)
1 line 18 (36)
2 lines 9 (18)




Table 1 Baseline characteristics (Continued)





CNS central nervous system, ECOG PS Eastern Cooperative Oncology Group
Performance Status
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change or addition of medication for glucose control (n = 1,
addition of metformin; n = 1, increase in dose of metfor-
min, addition of glimepiride; n = 1, increase in dose of met-
formin, addition of insulin).
Results of neuropsychiatric assessments using the PHQ-9
and GAD-7 instruments are displayed in Table 4. Comple-
tion rates of the instruments exceeded 70% at all timepoints.
Moderate (grade 2) depressive symptoms were reported by
11 (22%) patients on study, and in 2 (4%) patients at baseline.
Moderate anxiety symptoms were reported by 8 (16%) pa-
tients on study, in contrast to 2 (4%) patients at baseline.
Three patients reported treatment-emergent grade 3 depres-
sive symptoms, one patient reported grade 3 anxiety symp-
toms, and one patient reported both treatment-emergent
grade 3 depressive and anxiety symptoms according to these
scales. Supplemental Table 2 collates data from patients with
at least one neuropsychiatric assessment by PHQ-9 or GAD-
7 showing a score ≥ 10, the corresponding reported psychi-
atric adverse events by CTCAE 4.0 by investigator assess-
ment, and medical management of psychiatric adverse
events. Of note, standard investigator-reported CTCAE psy-
chiatric adverse events (e.g., depression, anxiety) underesti-
mated psychiatric symptoms as compared to patient-
reported neuropsychiatric outcomes as assessed with the
PHQ-9 and GAD-7 scales.
Correlative studies
Targeted DNA sequencing was performed using MSK-
IMPACT testing on archival or research tumor tissue bi-
opsies. Gene single-nucleotide variants (SNV) and copy
number variation (CNV) results were available in tumor
samples from 27 patients, including 20 archival FFPE
samples and 7 research core biopsies (baseline, n = 5;
C1D28, n = 2). Of these 27 samples, 6 (22.2%) harbored
an alteration in PIK3CA (E542K mutation, n = 1), AKT1
(E17K mutation, n = 1; AKT1 amplification, n = 1), or
PTEN (D24H mutation, n = 1; K237fs mutation, n = 1;
PTEN deep deletion, n = 1). In the sample with PTEN
deletion (log ratio − 2.87), the TP53 variant allele fre-
quency was 0.57, supporting likely homozygous loss of
PTEN. Additional alterations in genes in the PI3K path-
way [20] are displayed in Fig. 2.
Table 2 Best response by RECIST 1.1
Response No. of patients (%)
Confirmed CR 0 (0)
Confirmed PR 0 (0)
SD≥ 4 months§ 6 (12)
SD < 4months 11 (22)
Progressive disease 20 (40)
Non-evaluable* 13 (26)
CR complete response, PR partial response, SD stable disease
§One patient had an unconfirmed PR
*12 patients discontinued treatment before first post-baseline assessment due
to clinical progression. One patient discontinued treatment before the first
post-baseline assessment due to unacceptable toxicity
Fig. 1 Kaplan-Meier curves for progression-free survival (a) and overall survival (b) in patients with metastatic, triple-negative breast cancer
treated with buparlisib. Median PFS was 1.8 months (95% confidence interval [CI] 1.6–2.3) and median OS was 11.2 months (95% CI 6.2–25)
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As specified in the “Patients and methods” section, the trial
was originally designed to evaluate predictive biomarkers of
response to buparlisib (with particular emphasis on alter-
ations in the PI3K/PTEN pathway), with potential expansion
cohorts enriched for the identified biomarkers. However, we
did not observe sufficient clinical activity to move on to ex-
pansion cohorts or to test for potential predictors of clinical
benefit. Thus, the ability to correlate genomic findings with
response to buparlisib was limited. In the six patients with
tumor alterations in PIK3CA, AKT1, or PTEN, the best over-
all response was SD < 4months (n = 3, including the two pa-
tients with AKT1-altered tumors and one patient with PTEN
K237fs mutation), progressive disease (n = 2), and non-
evaluable (n = 1). Of the remaining 21 patients without iden-
tified alterations in PIK3CA/AKT1/PTEN, the best overall
response was SD ≥ 4months (n = 1), SD < 4months (n = 4),
progressive disease (n = 7), and non-evaluable (n = 9). In the
single patient who achieved clinical benefit ≥ 4months from
buparlisib with available SNV/CNV results, splicing muta-
tions in TP53 and RB1 were identified in the baseline meta-
static research biopsy.
Seventeen patients underwent a baseline biopsy, 6 of
them had sufficient tissue for proteomic analysis and 5
patients had available paired baseline and on-treatment
biopsies. Baseline samples (n = 6) were analyzed by
RPPA and compared with the TCGA dataset (Fig. 3,
SU2C samples in black are located in close proximity to
triple-negative breast cancer samples from TCGA in
red). All samples from this study clustered among the
TCGA triple-negative breast tumors. As shown in Fig. 3,
Table 3 All grade adverse events reported in ≥10% of patients or any reported grade 3 events (all relatedness), n = 50
AE description Number (%) of AE by CTCAE grading
Frequency G1 G2 G3 Total*
Fatigue 15 (30) 10 (20) 4 (8) 29 (58)
Nausea 12 (24) 5 (10) 0 (0) 17 (34)
Hyperglycemia 14 (28) 1 (2) 2 (4) 17 (34)
Anorexia 12 (24) 2 (4) 1 (2) 15 (30)
QTc prolongation 10 (20) 3 (6) 0 (0) 13 (26)
Alanine aminotransferase increased 3 (6) 2 (4) 5 (10) 10 (20)
Anxiety 5 (10) 4 (8) 0 (0) 9 (18)
Depression 6 (12) 3 (6) 0 (0) 9 (18)
Diarrhea 8 (16) 1 (2) 0 (0) 9 (18)
Aspartate aminotransferase increased 3 (6) 1 (2) 4 (8) 8 (16)
Psychiatric disorders—other 4 (8) 3 (6) 0 (0) 7 (14)
Gastrointestinal disorders—other 5 (10) 0 (0) 1 (2) 6 (12)
Rash acneiform 5 (10) 0 (0) 1 (2) 6 (12)
Constipation 6 (12) 0 (0) 0 (0) 6 (12)
Cough 5 (10) 1 (2) 0 (0) 6 (12)
Insomnia 6 (12) 0 (0) 0 (0) 6 (12)
Pain 1 (2) 5 (10) 0 (0) 6 (12)
Dyspnea 2 (4) 3 (6) 0 (0) 5 (10)
Mucositis oral 4 (8) 1 (2) 0 (0) 5 (10)
Rash maculo-papular 0 (0) 0 (0) 2 (4) 2 (4)
Alkalosis 0 (0) 0 (0) 1 (2) 1 (2)
Dry skin 0 (0) 0 (0) 1 (2) 1 (2)
Hepatic failure 0 (0) 0 (0) 1 (2) 1 (2)
Hyponatremia 0 (0) 0 (0) 1 (2) 1 (2)
Nervous system disorders—other 0 (0) 0 (0) 1 (2) 1 (2)
Pain in extremity 0 (0) 0 (0) 1 (2) 1 (2)
Papulopustular rash 0 (0) 0 (0) 1 (2) 1 (2)
Skin and subcutaneous tissue disorders—other 0 (0) 0 (0) 1 (2) 1 (2)
AE adverse event, CTCAE Common Terminology Criteria for Adverse Events, G grade
*No grade 4 or 5 events were reported
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five out of six exhibited a PI3K score consistent with
PI3K pathway activation. We further analyzed the PI3K
pathway downmodulation after treatment with buparli-
sib in the five patients exhibiting an activated PI3K sig-
nature in whom a paired on-treatment biopsy was also
available (Fig. 4). Integral downmodulation of key nodes
in the pathway including AKT S473, S6 S235/S236, S6
S240/S244, 4EBP1 S65, and 4EBP1 T37/T46 was exclu-
sively observed in two paired patient samples (Pt01,
Pt02), albeit there was evidence of concomitant feedback
activation on AKT T308 and p70S6K T389. With regards
to treatment response, these two patients experienced dis-
ease stabilization, along with Pt04, for whom there was no
pathway modulation observed. Pt03 and Pt05 experienced
progressive disease as the best overall response and their
tumor samples showed no change in S6 phosphorylation.
As previously suggested by Elkabets et al. for the PI3Kα
inhibitor alpelisib, reduction of S6 phosphorylation ap-
peared to be a key component of pathway modulation as-
sociated to treatment response [21].
Discussion
Given the observation that the majority of triple-negative
breast tumors demonstrate activation of the PI3K path-
way, we tested the pan-class I PI3K inhibitor buparlisib in
this phase 2 trial. In a small subset of patients in whom
paired baseline and on-treatment tumor biopsies were
available, we observed evidence of target inhibition in 2 of
3 patients with SD as best response, and none of 2 patients
with progressive disease as best response. Overall, only
12% of patients achieved prolonged SD, and we did not
observe any confirmed objective responses. In those with
available targeted panel DNA sequencing results, genomic
alterations in PIK3CA, AKT1, or PTEN were present in 3
of 8 (37.5%) patients who achieved SD, and in 2 of 9
(22.2%) patients with progressive disease as best overall re-
sponse. Median PFS for the overall study population was
less than 2months. Given the lack of a strong clinical sig-
nal, we chose not to open expansion cohorts in molecu-
larly selected subsets of triple-negative breast cancer.
Other trials have demonstrated that treatment with
single-agent inhibitors of the PI3K pathway has only lim-
ited efficacy in patients with metastatic breast cancer,
whether unselected [10] or selected for the presence of
PIK3CA/AKT/PTEN alterations in the tumor [22]. Our
study adds to the previous reports by demonstrating that
buparlisib has essentially no single-agent activity in un-
selected triple-negative breast cancer, and the develop-
ment of buparlisib has been discontinued in breast
cancer. The toxicity profile we observed is in keeping
with other reports of buparlisib at the studied dose and
schedule. Notably, any grade anxiety and any grade de-
pression were reported in 18% of patients. Buparlisib is
one of the PI3K inhibitors with highest blood-brain bar-
rier penetration [23]. However, the physiopathology of
mood disorders associated with pan-PI3K inhibitors has
not been well characterized, and it remains unclear
whether the higher incidence of neuropsychiatric effects
observed with buparlisib compared to isoform-selective
PI3K inhibitors is due to its elevated CNS penetration or
to other pharmacokinetic differences. Pan-PI3K inhibi-
tors have broader off-target effects, in addition to on-
target inhibition of each of the class I PI3K catalytic
Table 4 Neuropsychiatric assessment
Completion rate of PHQ-9 and GAD-7 scales by timepoint
PHQ-9 No. patients required No. patients
completed (% of
required)








Cycle 3 day 1 19 15 (79)
Off treatment 50 36 (72)
GAD-7 No. patients required No. patients
completed (% of
required)








Cycle 3 day 1 19 15 (79)













Baseline 49 33 (67) 14 (29) 2 (4) 0 (0)
Highest grade
on study
50 11 (22) 24 (48) 11 (22) 4 (8)
GAD-7
Baseline 49 33 (67) 14 (29) 2 (4) 0 (0)
Highest grade
on study
50 21 (42) 19 (38) 8 (16) 2 (4)
Change to medications for mood disorder
Total (n = 50), n (%)
No - 45 (90)
Yes - 5 (10)
PHQ-9 and GAD-7 Score Severity CTCAE grading: 0–4 normal; 5–9 grade 1; 10–
14 grade 2; ≥ 15 grade 3
GAD-7 Generalized Anxiety Disorder Scale, PHQ-9 Patient
Health Questionnaire-9
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isoforms, thus resulting in a less favorable toxicity profile
compared to selective p110-alpha inhibitors [24].
Of interest is the role of combining PI3K inhibitors
with other therapeutic modalities. Based on preclinical
data suggesting that adding a PI3K inhibitor to endo-
crine therapy may overcome resistance, two large phase
3 clinical trials, BELLE-2 [25] and BELLE-3 [26], evalu-
ated the efficacy of buparlisib plus fulvestrant versus pla-
cebo plus fulvestrant in postmenopausal patients with
ER-positive breast cancer refractory to aromatase inhibi-
tors. In addition, BELLE-3 required patients to be resist-
ant to mTOR inhibitors. Both trials met their primary
endpoint in the full population with the combination
leading to modest increases in PFS. Safety data were
consistent with that previously seen with buparlisib-
based regimens, with transaminase elevation and hyper-
glycemia as the most common grade 3–4 adverse events.
Among patients with ER-positive breast cancer whose
tumors harbor an activating PIK3CA mutation, results of
the SOLAR-1 trial demonstrated a clear PFS improve-
ment with the alpha-specific PI3K inhibitor, alpelisib, in
combination with fulvestrant [27]. Similarly, in the
SANDPIPER trial, patients with PIK3CA-mutant tumors
reportedly had increased median PFS with the addition
of taselisib (mutant-selective PI3K inhibitor) to fulves-
trant [28].
Other studies have evaluated combinatorial ap-
proaches of PI3K pathway inhibition with chemotherapy.
In a phase 1 dose escalation study of buparlisib com-
bined with capecitabine in patients with metastatic
breast cancer (n = 25), one patient with triple-negative
breast cancer treated at the maximum-tolerated dose
(buparlisib 100 mg daily; capecitabine 1000mg/m2 twice
daily) achieved a CR after receipt of 11 cycles of therapy,
and ultimately discontinued treatment after 32 cycles
due to mood changes [29]. Genomic testing confirmed
that the tumor was of basal-like intrinsic subtype, with-
out evidence of an activating PIK3CA mutation. Four
additional patients (two with ER-positive, one with
HER2-positive, and one with triple-negative breast can-
cer) exhibited a PR to treatment, and the remaining 12
evaluable patients experienced SD, suggesting potential
clinical activity. In contrast, the randomized phase 2 trial
comparing buparlisib plus paclitaxel versus placebo plus
paclitaxel in patients with HER2-negative breast cancer
was stopped early for futility, as the addition of the PI3K
Sample time point
Sample type
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Fig. 2 Co-mutation/CNV plot of tumor samples analyzed with targeted next-generation sequencing. Co-mutation and copy number variation
plot for samples analyzed with MSK-IMPACT panel testing (n = 27 samples; n = 27 patients). Included here are genes related to PI3K pathway and
drug resistance with at least one identified alteration in the cohort. Best overall response is displayed for each patient. Six samples harbored an
alteration in PIK3CA (E542K mutation, n = 1), AKT1 (E17K mutation, n = 1; AKT1 amplification, n = 1), or PTEN (D24H mutation, n = 1; K237fs
mutation, n = 1; PTEN deep deletion, n = 1). Alterations in PIK3CA, AKT1, or PTEN were observed in 3 of 8 patients (37.5%) who achieved SD, and
in 2 of 9 (22.2%) patients with progressive disease as best overall response
Garrido-Castro et al. Breast Cancer Research          (2020) 22:120 Page 8 of 13
inhibitor failed to demonstrate a significant PFS im-
provement in either the overall study population or in
the prespecified cohort of patients with PI3K-activated
tumors [30]. In the hormone receptor-negative popula-
tion enrolled on the study (99/416 patients, 24%), me-
dian PFS was numerically inferior with buparlisib
compared to placebo (5.5 vs. 9.3 months, respectively).
Notably, ipatasertib, a selective AKT inhibitor, improved
PFS in combination with paclitaxel (compared to pla-
cebo plus paclitaxel) as first-line therapy for metastatic
triple-negative breast cancer in the LOTUS phase 2 trial
[31]. This benefit was observed in both the intent-to-
treat population (6.2 vs. 4.9 months, hazard ratio [HR]
0.60) and in patients with PIK3CA/AKT/PTEN-altered
tumors (9.0 vs. 4.9 months, HR 0.44), leading to the
design of the ongoing randomized phase 3 trial explor-
ing the combination in preselected triple-negative breast
cancer with activation of the PI3K pathway
(NCT03337724). The addition of capivasertib, another
selective AKT inhibitor, to paclitaxel also significantly
increased PFS, with a trend toward longer OS, in pa-
tients with prespecified alterations in PI3KCA, AKT, or
PTEN; however, this benefit was not seen in patients
















































































































































Fig. 3 Unsupervised clustering and PI3K signature score based on the RBN dataset. Heatmap depicting protein levels after unsupervised hierarchical
clustering of 826 TCGA samples plus 6 baseline SU2C samples and 128 antibodies. Protein levels are indicated on a low-to-high scale (green-black-red).
Annotation bars include the PAM50 intrinsic subtype classification. The PI3K score is shown in the lower panel. SU2C samples (black) are located in
close proximity to triple-negative breast cancer samples from TCGA (red)
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activity will be explored in an ongoing randomized phase
3 study which will enroll patients with untreated locally
advanced or metastatic triple-negative breast cancer
(NCT03997123). Similarly, the alpha-specific PI3K in-
hibitor alpelisib showed promising activity in combin-
ation with albumin-bound paclitaxel in patients with
metastatic HER2-negative breast cancer, most (30/43,
70%) of whom had received at most one prior line of
chemotherapy in the metastatic setting [33]. In the triple-
negative breast cancer subgroup with available response
data, unselected for PI3K status, the objective response
rate was 58% (7/12). In the overall study population, nu-
merically greater objective response rate (74% vs. 48%),
clinical benefit rate (100% vs. 61%), and median PFS (13
vs. 7 months, HR 0.40) were observed among patients with
PI3K pathway-activation compared to those without
PIK3CA-activating or PTEN-inactivating mutations, lead-
ing to the design of an ongoing phase 3 randomized study
of alpelisib or placebo plus albumin-bound paclitaxel as
first- or second-line therapy for patients with PIK3CA-
mutant or PTEN loss (without PIK3CA mutation) ad-
vanced triple-negative breast cancer (NCT04251533).
It is unclear whether the lack of effectiveness of treat-
ment with single-agent pan-PI3K inhibitors in triple-
negative breast cancer is related to adaptive activation of
compensatory signaling pathways or due to a failure to
achieve sufficient target inhibition and PI3K pathway
suppression due to toxicity. PTEN loss has been found
to lead to a convergent PTEN-null phenotype resistant
to PI3K-alpha inhibition [34]. Given that 60% of triple-
negative breast cancers harbor PTEN genomic
alterations [7, 8], it would be important to define
whether such alterations could also be responsible for de
novo resistance to PI3K inhibitors as well. Furthermore,
given the variable efficacy of targeting the PI3K pathway
to date in unselected or PI3K-activated triple-negative
breast cancer, additional biomarker analyses are needed
to better understand the putative oncogenic role of these
genes in this breast cancer subtype.
Our study had several limitations. First, we tested only
single-agent buparlisib and cannot rule out that combination
therapies might provide additional efficacy. Since we initiated
this study, the treatment landscape for patients with meta-
static triple-negative breast cancer has evolved considerably,
and two targeted approaches were recently approved: the
anti-PD-L1 inhibitor atezolizumab in combination with nab-
paclitaxel in PD-L1-positive triple-negative breast cancer
[35], and the PARP inhibitors olaparib or talazoparib for
germline BRCA1/BRCA2 mutation carriers [36, 37]. There
are now preliminary data supporting the molecular rationale
to test combinations of PI3K inhibitors with these agents
[38]. For example, based on a strong preclinical synergistic
signal combining buparlisib and olaparib [39], a phase 1 clin-
ical trial evaluating the combination was launched in ad-
vanced triple-negative breast cancer and ovarian carcinoma
[40]. Results of the study demonstrated feasibility and prom-
ising anti-cancer activity for this combination, though trans-
aminase elevations and neuropsychiatric adverse events were
common and responsible for dose-limiting toxicities. There
are also emerging data that PTEN loss is associated with re-
sistance to immunotherapy, raising the question of whether
combinations of inhibitors of PI3K/AKT/mTOR signaling
Fig. 4 Unsupervised clustering based on the delta values of the paired samples. Heatmap depicting the delta values in the paired samples of the
PI3K signature-related proteins ordered from upstream (top) to downstream (bottom). Protein levels are indicated on a low-to-high
scale (green-black-red)
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with immune checkpoint inhibitors could provide additional
clinical efficacy [41]. Second, although we had originally de-
signed the study to evaluate predictive biomarkers of re-
sponse to buparlisib, with potential expansion cohorts
enriched for the identified biomarkers, we did not observe
sufficient clinical activity to move on to expansion cohorts or
to test for potential predictors of clinical benefit. In addition,
we could not establish if the degree of PI3K downmodula-
tion was sufficient to be consistent with antitumor activity.
Conclusions
In summary, buparlisib, when given as a single agent
in patients with triple-negative breast cancer, was not
associated with a strong clinical signal of efficacy,
though a small subset of patients did achieve pro-
longed SD. Downmodulation of key nodes in the
PI3K pathway was observed in patients who achieved
tumor stabilization. The toxicity profile of buparlisib
was consistent with previous reports, highlighting the
pharmacological limitations of pan-PI3K inhibition
compared to selective PI3K isoform inhibitors that
may achieve improved efficacy with fewer side effects.
Although our results do not support additional testing
of single-agent PI3K inhibitors in triple-negative
breast cancer, they do not preclude the potential
benefit for the efficacy of rational combinations in-
cluding selective PI3K pathway inhibitors.
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